Board of Directors
Beth Seidenberg, M.D. — Kleiner Perkins Caufield & Byers (KPCB)
Beth joined Kleiner Perkins Caufield & Byers in May 2005 to work in the life sciences area. Beth was formerly the Senior Vice President, Global Development, and Chief Medical Officer at Amgen. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb and Merck & Co. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. In total, she introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis. She is currently on the Board of Directors of 3-V Biosciences, Arresto Biosciences, BioCryst Pharmaceuticals, Breathe Technologies, Epizyme, iPierian, Inc, and RedBrick Health. Her primary focus is in novel therapeutics to treat unmet medical needs.
Beth received her B.S. from Barnard College and her medical degree from the University Of Miami School Of Medicine. Her post-graduate training was completed at Johns Hopkins and the National Institutes of Health.
Mark Gudiksen, Ph.D — TPG Biotech
Prior to joining TPG Biotech in 2008, Mark Gudiksen was an Engagement Manager in McKinsey & Company’s west coast healthcare practice. At McKinsey, he worked on a broad spectrum of strategic topics and M&A opportunities with a variety of clients, including biopharmaceutical & medical device companies, hospital chains, and private equity firms. In addition to serving on the Board of Directors of Auxogyn, Inc., Mark is also a board observer for Nodality, Inc.
Mark received his Ph.D. in chemical physics from Harvard, and his B.S. in chemistry from Stanford. Mark’s doctoral work in nanotechnology was recognized with several highly cited publications in leading scientific journals, such as Science and Nature, as well as general audience publications as broad as Scientific American and the Wall Street Journal.
Simeon George, M.D. — SR One
Simeon George joined SR One in 2007 and leads SR One’s investment activities on the West Coast. Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch. Simeon is a member of the Board of Directors of Anaphore, Auxogyn, Inc., Genocea Biosciences, HTG Molecular, Principia Biosciences and Semprus BioSciences.
Simeon received his B.A. in Neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa. Simeon received his MD from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania.
Nilesh Kumar, P.h.D — Merck Serono Ventures
Nilesh Kumar is Director at Merck Serono Ventures, where he invests in life science technology companies. Prior to Merck Serono Ventures, Nilesh has worked at Infinity Pharmaceuticals, Codon Devices, and Atlas Ventures. In addition to serving on the Board of Directors of Auxogyn, Inc., Nilesh serves as Observer on f-Star Board.
Nilesh received his doctoral degree in chemical biology and an MBA from Harvard University.
Lissa Goldenstein — President & CEO and Co-Founder
Lissa Goldenstein is a co-founder of Auxogyn and serves as President and CEO. Prior to joining Auxogyn, Lissa was President and CEO of Artemis Health, Inc. (now Verinata Health, Inc), a venture-backed company focused on developing non-invasive prenatal diagnostic tests, where she defined the business strategy, broadened the product and intellectual property portfolio and secured more than $20 million in funding over a three year period. Prior to Artemis Health, Lissa was President and CEO of Argonaut Technologies, Inc. (NASDAQ: AGNT) from 2001 to 2005. Lissa currently serves on the Board of Directors of Argonaut Technologies and was previously on the Board of Directors for OtisMed Corporation, which was recently acquired by Stryker Corporation. Lissa is a seasoned senior executive with over 30 years of leadership experience in life science companies.
Lissa received her B.S. in Architectural Engineering from Pennsylvania State University and received her Professional Engineers license as a structural engineer in the State of California.
Kathryn A. Tunstall — Chairman of the Board
Kathryn A. Tunstall is Chairman of the Board of Directors of Conceptus, Inc., a publicly- held women’s healthcare company, a position she has held since January 2000. Ms Tunstall served as the Company’s first President and Chief Executive Officer from July 1993 to December 1999 and has continuously served as a director of the Company since her appointment as CEO. Conceptus and its Essure Permanent Birth control device and procedure have been awarded many honors including the peer-awarded Phoenix Award for Medical Technology Innovation and most recently the Company was nominated for the National Medal of Technology and Innovation (NMTI), the nation’s highest honor for technological achievement, bestowed by the president of the United States on America’s leading innovators. Prior to joining Conceptus, from June 1990 until June 1993, Ms. Tunstall served as President of the Edwards Less Invasive Surgery Division of Baxter International, a division engaged in the development, manufacturing and marketing of cardiovascular catheters. Prior to her appointment as Division President, after joining the Company in November, 1986, Ms. Tunstall served as Vice President of Worldwide Sales and Marketing,. From 1974 to 1986, Ms. Tunstall held various positions in finance, operations and marketing in two divisions of American Hospital Supply Corporation, including that of Vice President of Marketing of McGaw Laboratories, a pharmaceutical and medical device company. From 2003 until its acquisition by Perkin Elmer, Inc. in November, 2011, Ms. Tunstall served as a director of Caliper LifeSciences, a publicly-traded biotechnology company. During her service as a director of Caliper, Ms. Tunstall served as Chair of both the Audit and Compensation Committees. Since 1989, Ms. Tunstall has been involved in the founding and early stage development of six private women’s healthcare companies. She has been active in several women’s health advocacy organizations.
Ms. Tunstall holds a B.A. degree in Economics from the University of California and has completed graduate level studies in Business and Healthcare Administration.